 |
53 Diseases |  |
490 Trials |
|
490 Trials |  |
8927 News |  |
| «12...6263646566676869707172...123124» |
- |||| Keytruda (pembrolizumab) / Merck (MSD), Lenvima (lenvatinib) / Eisai, Merck (MSD)
New P2 trial, Metastases: Efficacy and Safety of Pembrolizumab in Combination With Lenvatinib in Metastatic Uveal MElanoma Patients (PLUME) (clinicaltrials.gov) - Mar 16, 2022
P2, N=54, Not yet recruiting, Sponsor: Institut Curie
- || lenvatinib / Generic mfg.
Clinical, Journal: The impact of individual human cytochrome P450 enzymes on oxidative metabolism of anticancer drug lenvatinib. (Pubmed Central) - Mar 15, 2022
It was even more efficient in forming of O-desmethyl lenvatinib than CYP3A4 in the absence of cytochrome b. The present study indicates that further research focused on drug-drug interactions, in particular on CYP3A4 and CYP1A1 modulators, is needed. This will pave new avenues towards TKIs-mediated personalized therapy.
- | AiRuiKa (camrelizumab) / Jiangsu Hengrui Medicine
Retrospective data, Journal, Monotherapy: Lenvatinib Plus Camrelizumab vs. Lenvatinib Monotherapy as First-Line Treatment for Unresectable Hepatocellular Carcinoma: A Multicenter Retrospective Cohort Study. (Pubmed Central) - Mar 15, 2022
Three patients in the L+C group and two in the L group terminated treatment owing to adverse events. First-line lenvatinib plus camrelizumab showed better effectiveness than lenvatinib alone in patients with unresectable HCC.
- | Enweida (envafolimab) / 3DMed, Ascletis
Enrollment open, Metastases: CISLD-12: Study on Therapeutic Effect of Combination of Envafolimab, Lenavatinib and TACE in Advanced HCC Patients (clinicaltrials.gov) - Mar 15, 2022
P2, N=39, Recruiting, Sponsor: Zhejiang University
First-line lenvatinib plus camrelizumab showed better effectiveness than lenvatinib alone in patients with unresectable HCC. Not yet recruiting --> Recruiting
- | AZD7003 / AstraZeneca
Enrollment open, CAR T-Cell Therapy, Metastases: A Study to Evaluate Safety and Efficacy of Armored CAR-T Cell Injection C-CAR031 in Advanced Hepatocellular Carcinoma (clinicaltrials.gov) - Mar 15, 2022
P1, N=20, Recruiting, Sponsor: Zhejiang University
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- || Lenvima (lenvatinib) / Eisai, Merck (MSD)
Enrollment closed: A Study of Lenvima (Lenvatinib) in Korean Unresectable Hepatocellular Carcinoma (uHCC) Participants (clinicaltrials.gov) - Mar 15, 2022
P=N/A, N=600, Active, not recruiting, Sponsor: Eisai Korea Inc.
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting
- Sutent (sunitinib) / Pfizer
Computerized tomography (CT)-based hepatic radiomics phenotypes associate with response to anti-angiogenics in neuroendocrine tumors (NETs): A subanalysis from the phase II TALENT clinical trial () - Mar 14, 2022 - Abstract #ENETS2022ENETS_240;
Introduction: The phase II TALENT clinical trial provided evidence of the efficacy of Lenvatinib in patients with panNETs and giNETs...Models were validated internally and tested in an external cohort of 26 patients with NETs treated with Sunitinib... Single-phase radiomics were able to predict clinical benefit from anti-angiogenic treatment based on the quantification of hypervascularization and tumor shape.
- lenvatinib / Generic mfg.
Identification of proangiogenic plasmatic biomarkers in patients with advanced grade 1/2 pancreatic (pan) and gastrointestinal (gi) neuroendocrine tumors (NETs) treated with Lenvatinib: A subanalysis from the TALENT phase II clinical trial () - Mar 14, 2022 - Abstract #ENETS2022ENETS_191;
High-Ang2 and low-FGF2 levels are associated to better response to lenvatinib in panNETs and giNETs and emerge as possible predictive factors of response to Lenvatinib. In Sunitinib-pretreated patients, Ang2 and VEGFR2 levels significantly predicted PFS and ORR in panNETs.
- || Keytruda (pembrolizumab) / Merck (MSD), Lenvima (lenvatinib) / Eisai, Merck (MSD)
Enrollment open, Trial initiation date, Metastases: MK-3475-A70: Pembrolizumab and Lenvatinib in Advanced Cervical Cancer (clinicaltrials.gov) - Mar 14, 2022
P2, N=35, Recruiting, Sponsor: Georgetown University
In Sunitinib-pretreated patients, Ang2 and VEGFR2 levels significantly predicted PFS and ORR in panNETs. Not yet recruiting --> Recruiting | Initiation date: Dec 2021 --> Mar 2022
- | New trial: Radiofrequency Ablation Plus Systematic Neoadjuvant Therapy for Recurrent Hepatocellular Carcinoma (RANT Study) (clinicaltrials.gov) - Mar 13, 2022
P=N/A, N=160, Recruiting, Sponsor: Southwest Hospital, China
- | Opdivo (nivolumab) / Ono Pharma, BMS, Cabometyx (cabozantinib tablet) / Takeda, Exelixis, Ipsen
Journal, Combination therapy, Checkpoint inhibition: The 2021 Updated European Association of Urology Guidelines on Renal Cell Carcinoma: Immune Checkpoint Inhibitor-based Combination Therapies for Treatment-naive Metastatic Clear-cell Renal Cell Carcinoma Are Standard of Care. (Pubmed Central) - Mar 11, 2022
The CheckMate-9ER trial update demonstrated an ongoing PFS, OS, and quality-of-life benefit for cabozantinib plus nivolumab over sunitinib as did the update of Keynote-426 for axitinib plus pembrolizumab in the intention-to-treat population, with a PFS benefit seen across all International Metastatic Database Consortium (IMDC) subgroups...PATIENT SUMMARY: New data from combination trials with immune checkpoint inhibitors for advanced kidney cancer confirm a survival benefit for lenvatinib plus pembrolizumab, cabozantinib plus nivolumab (with improved quality-of-life), axitinib plus pembrolizumab, and ipilimumab plus nivolumab. These combination therapies are recommended as first-line treatment for advanced kidney cancer.
- || Nexavar (sorafenib) / Bayer, Amgen
Clinical, Journal: Transarterial chemoembolization plus lenvatinib versus transarterial chemoembolization plus sorafenib as first-line treatment for hepatocellular carcinoma with portal vein tumor thrombus: A prospective randomized study. (Pubmed Central) - Mar 11, 2022
P4
These combination therapies are recommended as first-line treatment for advanced kidney cancer. TACE plus lenvatinib was safe, well tolerated, and had favorable efficacy versus TACE plus sorafenib in patients with advanced HCC with PVTT and large tumor burden.
- | lenvatinib / Generic mfg.
Journal: circKCNN2 suppresses the recurrence of hepatocellular carcinoma at least partially via regulating miR-520c-3p/methyl-DNA-binding domain protein 2 axis. (Pubmed Central) - Mar 11, 2022
Inherent level of circKCNN2 in HCC cells predisposes anti-tumor effect of lenvatinib possibly because both circKCNN2 and lenvatinib repress the expression of FGFR4. circKCNN2 may be a promising predictive biomarker and therapeutic agent for HCC recurrence.
- | Cabometyx (cabozantinib tablet) / Takeda, Exelixis, Ipsen
Preclinical, Journal: Volumetric absorptive microsampling (VAMS) for the quantification of ten kinase inhibitors and determination of their in vitro VAMS-to-plasma ratio. (Pubmed Central) - Mar 11, 2022
The assay includes the KI cabozantinib, dabrafenib, nilotinib, and osimertinib with a calibration range of 6-1500 ng/mL and afatinib, axitinib, bosutinib, lenvatinib, ruxolitinib and trametinib within a range of 2-500 ng/mL...The method was successfully used in a real-life setting demonstrating its applicability in clinical routine. VAMS concentrations of afatinib, cabozantinib, dabrafenib, nilotinib, ruxolitinib and trametinib were assessed in capillary blood samples collected from either trained healthcare professionals or patients at home.
- | lenvatinib / Generic mfg.
Retrospective data, Journal: The Geriatric Nutritional Risk Index Predicts Tolerability of Lenvatinib in Patients With Hepatocellular Carcinoma. (Pubmed Central) - Mar 11, 2022
VAMS concentrations of afatinib, cabozantinib, dabrafenib, nilotinib, ruxolitinib and trametinib were assessed in capillary blood samples collected from either trained healthcare professionals or patients at home. The GNRI might be independently associated with the tolerability of lenvatinib in patients with HCC.
- | lenvatinib / Generic mfg.
Biomarker, Retrospective data, Journal: Prognostic role of multiparameter MRI and radiomics in progression of advanced unresectable hepatocellular carcinoma following combined transcatheter arterial chemoembolization and lenvatinib therapy. (Pubmed Central) - Mar 11, 2022
Furthermore, it can increase the accuracy of a combined model for predicting disease progression. In order to improve clinical outcomes, clinicians may use this to select an optimal treatment strategy and develop a personalized monitoring protocol.
- || lenvatinib / Generic mfg.
Retrospective data, Review, Journal: Reply: Clinical efficacy of lenvatinib for the treatment of radioiodine-refractory thyroid carcinoma: A systematic review and meta-analysis of clinical trials. (Pubmed Central) - Mar 11, 2022
In order to improve clinical outcomes, clinicians may use this to select an optimal treatment strategy and develop a personalized monitoring protocol. Dear Editor, we read with great interest the paper by Zhipeng et al, sharing the perspective that lenvatinib is beneficial for the treatment of radioiodine-refractory thyroid cancer in terms of the extension of progression-free survival (PFS) and overall survival (OS).
- | Avastin (bevacizumab) / Roche, Nexavar (sorafenib) / Bayer, Amgen
Journal, Real-world evidence: Efficacy of Lenvatinib and Sorafenib in the Real-World First-Line Treatment of Advanced-Stage Hepatocellular Carcinoma in a Taiwanese Population. (Pubmed Central) - Mar 11, 2022
Lenvatinib, compared to sorafenib, had better ORR and DCR, but similar OS, in Taiwanese patients with advanced-stage HCC. The patients with an objective tumor response had a better OS.
- ||| lenvatinib / Generic mfg.
PhIII LAUNCH study of 1L #lenvatinib + #TACE (w/repeat TACE allowed) vs lenvatinib in adv #HCC showing #OS benefit of combo vs len alone and improved ORR. Data showing TKI + locoregional therapies growing in Asia, applicability in West w/o RCT in West? #GI22 (Twitter) - Mar 10, 2022
- | Keytruda (pembrolizumab) / Merck (MSD), Lenvima (lenvatinib) / Eisai, Merck (MSD)
New P1 trial: A Pilot Study to Assess Changes in Tumor Biology Following Second-line Treatment With Pembrolizumab Plus Lenvatinib in Patients With Advanced Pancreatic Ductal Adenocarcinoma (clinicaltrials.gov) - Mar 9, 2022
P1, N=15, Not yet recruiting, Sponsor: M.D. Anderson Cancer Center
- || Cabometyx (cabozantinib tablet) / Takeda, Exelixis, Ipsen, Nexavar (sorafenib) / Bayer, Amgen
Review, Journal: Molecular targets of tyrosine kinase inhibitors in thyroid cancer. (Pubmed Central) - Mar 9, 2022
Lenvatinib and sorafenib reached the approval for RAI-refractory DTC, whereas cabozantinib and vandetanib for MTC...Severe side effects and drug resistance can develop in TC patients treated with TKIs. Additional studies are needed to identify a potential effective targeted therapy for aggressive TCs, according to their molecular characterization.
- | Nexavar (sorafenib) / Bayer, Amgen
Preclinical, Journal: Predicting HCC Response to Multikinase Inhibitors with In Vivo Cirrhotic Mouse Model for Personalized Therapy. (Pubmed Central) - Mar 9, 2022
Additional studies are needed to identify a potential effective targeted therapy for aggressive TCs, according to their molecular characterization. A clinically relevant cirrhotic PDX model preserves tumor angiogenesis and allows prediction of response to multikinase inhibitors for personalized therapy.
- | Tuoyi (toripalimab) / Shanghai Junshi Biosci, Coherus Biosci
Retrospective data, Journal: Toripalimab Combined With Hepatic Arterial Infusion Chemotherapy Versus Lenvatinib for Advanced Hepatocellular Carcinoma. (Pubmed Central) - Mar 9, 2022
In the propensity score-matched cohorts (47 pairs), the outcomes in the TorHAIC group were also better than those in the lenvatinib group (p < .05). Toripalimab plus HAIC was tolerable and effective in advanced HCC and the result needs to be confirmed in the phase III trial.
- ||| Clinical guideline, Journal: AGA Clinical Practice Guideline on Systemic Therapy for Hepatocellular Carcinoma. (Pubmed Central) - Mar 9, 2022
Toripalimab plus HAIC was tolerable and effective in advanced HCC and the result needs to be confirmed in the phase III trial. The Panel agreed on 11 recommendations focused on systemic therapy for HCC in patients who are not eligible for locoregional therapy or resection, those with metastatic disease and preserved liver function, those with poor liver function, and those on systemic therapy as adjuvant therapy.
- lenvatinib / Generic mfg.
ANTI-TUMOR EFFICACY OF LENVATINIB IN HUMAN HEPATOCARCINOMA: ROLE OF AUTOPHAGY-MEDIATED NRP1 DEGRADATION () - Mar 9, 2022 - Abstract #AEEH2022AEEH_45;
- lenvatinib / Generic mfg.
Anti-tumor effects of lenvatinib plus anti-PD-1 in syngeneic murine cervical cancer models (E-Poster Website) - Mar 9, 2022 - Abstract #AACR2022AACR_7141;
Furthermore, the lenvatinib plus aPD-1 combination group reduced tumor volume to 110mm3 on the 24th day after injection and it was significantly different compared to each single treatment group (P=0.13868 and P=0.27385, respectively).In this study, anti-tumor effect of aPD-1 was enhanced by the regulation of tumor microenvironment with lenvatinib in immunocompetent murine cervical cancer models. In conclusion, addition of lenvatinib is expected to increase the efficacy of ICIs in patients with cervical cancer who have the resistance or insensitivity to ICIs.
- lenvatinib / Generic mfg.
Development of a novel gene expression signature that correlates with intratumor microvessel density and antitumor activity of lenvatinib (E-Poster Website) - Mar 9, 2022 - Abstract #AACR2022AACR_6582;
They also showed higher MVD gene score calculated from RNA-seq data.Our newly developed MVD gene score has a potential to predict the antitumor activity of angiogenic inhibitors such as lenvatinib using RNA-seq data in tumor samples. Further validation study is ongoing using various human tumor samples.
- Nexavar (sorafenib) / Bayer, Amgen
Mouse models of hepatocellular carcinoma: A comprehensive and functional preclinical platform for immunotherapy research (Section 12) - Mar 9, 2022 - Abstract #AACR2022AACR_4358;
Treatment of mice with lenvatinib alone or in combination with anti-PD1 increases survival and reduces tumor burden as shown with reduced liver weight/body weight ratio at 16 weeks. Altogether, these results demonstrate the usefulness of this comprehensive platform of preclinical in vivo HCC models to discover and identify novel therapeutic strategies that could circumvent the progression of liver cancers.
- | Lenvima (lenvatinib) / Eisai, Merck (MSD)
Trial initiation date: Lenvatinib for the Treatment of Recurrent Hepatocellular Carcinoma After Liver Transplant (clinicaltrials.gov) - Mar 9, 2022
P2, N=19, Not yet recruiting, Sponsor: Emory University
Altogether, these results demonstrate the usefulness of this comprehensive platform of preclinical in vivo HCC models to discover and identify novel therapeutic strategies that could circumvent the progression of liver cancers. Initiation date: Jan 2022 --> Jul 2022
- | Keytruda (pembrolizumab) / Merck (MSD), lenvatinib / Generic mfg.
One of the rare Pembro Lenva failures.. (Twitter) - Mar 8, 2022
- Keytruda (pembrolizumab) / Merck (MSD)
Network Meta-Analysis (NMA) to Assess Comparative Efficacy of Lenvatinib Plus Pembrolizumab Compared with Other First-Line Treatments for Management of Advanced Renal Cell Carcinoma (ARCC) (In-person & Virtual) - Mar 8, 2022 - Abstract #ISPOR2022ISPOR_758;
Greater than 75% probability of CR benefit was observed across 13 of 14 comparators. CONCLUSION : The NMA results show that combination therapy with LEN+PEM provides a substantial likelihood of clinically meaningful improvements in OS, PFS, and response outcomes compared with the majority of current global standard of care treatment options for treatment-naïve aRCC patients.
- Estimated Costs for All-Cause Grade 3/4 Adverse Events Among First-Line Tyrosine Kinase Inhibitor Plus Immuno-Oncology-Based Combination Therapies for Patients with Advanced Renal Cell Carcinoma from the United States Perspective (In-person & Virtual) - Mar 8, 2022 - Abstract #ISPOR2022ISPOR_750;
OBJECTIVES: Three tyrosine kinase inhibitor + immuno-oncology (TKI+IO) regimens (i.e., cabozantinib+nivolumab [C+N], axitinib+pembrolizumab [A+P], and lenvatinib+pembrolizumab [L+P]) have been approved by the Food and Drug Administration (FDA) for the first-line treatment of advanced renal cell carcinoma (aRCC)...The top AE cost driver was increased lipase for two of the regimens under study. Our study suggests that AE costs vary among TKI+IO regimens and could be important in assessing cost-effectiveness and budget impacts.
- Comparison of Network Meta-Analysis Methodologies Used to Assess First-Line Treatments in Renal Cell Carcinoma: A Systematic Review (Virtual) - Mar 8, 2022 - Abstract #ISPOR2022ISPOR_219;
The validity of published NMA results comparing 1L CaboNivo versus alternative combination therapies for aRCC are limited by their reliance on the PH assumption. A more robust NMA that uses survival models with parameters for shape and scale, using the full Kaplan–Meier curves, is warranted to offer more reliable comparative outcome estimates, including long-term estimates, for 1L combination aRCC therapies.
- Opdivo (nivolumab) / Ono Pharma, BMS, Cabometyx (cabozantinib tablet) / Takeda, Exelixis, Ipsen
Cost Effectiveness of Cabozantinib Plus Nivolumab As First-Line Treatment for Renal Cell Carcinoma () - Mar 8, 2022 - Abstract #ISPOR2022ISPOR_3;
P3
Under a lifetime horizon (50-years), patients entered the model in the progression-free state and received 1L CaboNivo or an alternative tyrosine kinase inhibitor (TKI; cabozantinib, pazopanib, temsirolimus, tivozanib, sorafenib, sunitinib) or combination (axitinib/avelumab, axitinib/pembrolizumab, ipilimumab/nivolumab, lenvatinib/pembrolizumab)... CaboNivo had a favourable cost-effectiveness profile compared to other globally available 1L treatment options when using French costs over a lifetime horizon.
- | cisplatin / Generic mfg., lenvatinib / Generic mfg.
Journal: Characterization of Cisplatin Effects in Lenvatinib-resistant Hepatocellular Carcinoma Cells. (Pubmed Central) - Mar 8, 2022
Proliferation of LR cells was induced upon ERK signaling activation. Cisplatin exerted antitumor effects in LR cells and was involved in the regulation of miRNAs associated with drug resistance.
- | Avastin (bevacizumab) / Roche, Tecentriq (atezolizumab) / Roche
Retrospective data, Journal: Current Role of Atezolizumab Plus Bevacizumab Therapy in the Sequential Treatment of Unresectable Hepatocellular Carcinoma. (Pubmed Central) - Mar 8, 2022
Atezolizumab plus bevacizumab therapy can be effective for advanced HCC irrespective of the patients' liver function and treatment line. Lenvatinib administration after atezolizumab plus bevacizumab therapy can be effective, although special attention should be paid to the deterioration of liver function.
- ||| lenvatinib / Generic mfg.
On @_Feedkast the top article on the #gastroenterology feed is from @DanengLi discussing REFLECT trial results of lenvatinib in HCC in an article published on @TargetedOnc: https://t.co/ptDXK00OkG. #oncology #CancerResearch (Twitter) - Mar 8, 2022
- |||||| Keytruda (pembrolizumab) / Merck (MSD), lenvatinib / Generic mfg.
Clinical: At 2022 ASCO GU, Toni K. Choueiri, MD, discussed the CLEAR study and how East Asian patients with renal cell carcinoma derived similar benefit with lenvatinib plus pembrolizumab as the overall trial population. @DrChoueiri @DanaFarber https://t.co/QjlMb77Uzn (Twitter) - Mar 8, 2022
- ||||| Keytruda (pembrolizumab) / Merck (MSD), lenvatinib / Generic mfg.
Clinical: First-line pembrolizumab with or without lenvatinib in patients with advanced #UrothelialCarcinoma (LEAP-011): a phase 3, randomized, double-blind study. Presented by @onthelastnews @GustaveRoussy. #GU22 written coverage by @WallisCJD @UofT > https://t.co/ldaT9i4Oj8 @ASCO (Twitter) - Mar 8, 2022
- | lenvatinib / Generic mfg.
Journal: Early Alpha-Fetoprotein Response Is Associated With Survival in Patients With HBV-Related Hepatocellular Carcinoma Receiving Lenvatinib. (Pubmed Central) - Mar 8, 2022
A subsequent multivariate analysis confirmed that early AFP response (HR, 0.387; 95% CI, 0.183-0.992; p=0.0154), Eastern Cooperative Oncology Group Performance Status of 0 (HR, 0.890; 95% CI, 0.811-0.976; p=0.0132) and Albumin-Bilirubin grade 1 (HR, 0.457; 95% CI, 0.269-0.963; p=0.0327) were independent prognostic factors for longer progression-free survival. AFP is an important prognostic factor and a predictive biomarker for survival benefit with lenvatinib treatment in patients with HBV-related uHCC.
- | lenvatinib / Generic mfg.
Journal: MicroRNA-128-3p Mediates Lenvatinib Resistance of Hepatocellular Carcinoma Cells by Downregulating c-Met. (Pubmed Central) - Mar 8, 2022
MiR-128-3p and c-Met participate in the mechanisms underlying lenvatinib resistance through regulating Akt that mediates the apoptotic pathway and ERK (extracellular-signal-regulated kinase) modulating cell cycle progression. The present results indicate that the miR-128-3p/c-Met axis may be potential therapeutic targets for circumventing lenvatinib resistance in HCC and warrant further investigation.
- ||| Lenvima (lenvatinib) / Eisai, Merck (MSD)
Trial completion: A Study of Overall Survival in Participants With Unresectable Hepatocellular Carcinoma (clinicaltrials.gov) - Mar 8, 2022
P=N/A, N=412, Completed, Sponsor: Eisai Co., Ltd.
The present results indicate that the miR-128-3p/c-Met axis may be potential therapeutic targets for circumventing lenvatinib resistance in HCC and warrant further investigation. Active, not recruiting --> Completed
- |||| Tevimbra (tislelizumab-jsgr) / BeiGene, Partruvix (pamiparib) / EMD Serono
Trial completion date, Trial primary completion date: BGB-A317-290-LTE1: Study of Tislelizumab, Pamiparib, and Other Investigational Agents in Participants With Advanced Malignancies (clinicaltrials.gov) - Mar 8, 2022
P3, N=300, Enrolling by invitation, Sponsor: BeiGene
Active, not recruiting --> Completed Trial completion date: Dec 2021 --> Dec 2022 | Trial primary completion date: Dec 2021 --> Dec 2022
- || Lenvima (lenvatinib) / Eisai, Merck (MSD)
Trial completion date, Trial primary completion date, Combination therapy: A Study to Compare the Efficacy and Safety of Ifosfamide and Etoposide With or Without Lenvatinib in Children, Adolescents and Young Adults With Relapsed and Refractory Osteosarcoma (clinicaltrials.gov) - Mar 8, 2022
P2, N=72, Active, not recruiting, Sponsor: Eisai Inc.
Trial completion date: Dec 2021 --> Dec 2022 | Trial primary completion date: Dec 2021 --> Dec 2022 Trial completion date: Dec 2022 --> May 2022 | Trial primary completion date: Dec 2022 --> May 2022
- |||||| erfonrilimab (KN046) / Alphamab
Enrollment open, Metastases: KN046 Plus Lenvatinib in Subject With Advanced Non-Small Cell Lung Cancer in the Failure of Anti-PD-(L)1 Agent (clinicaltrials.gov) - Mar 8, 2022
P2/3, N=522, Recruiting, Sponsor: Jiangsu Alphamab Biopharmaceuticals Co., Ltd
Trial completion date: Dec 2022 --> May 2022 | Trial primary completion date: Dec 2022 --> May 2022 Not yet recruiting --> Recruiting
- || Lenvima (lenvatinib) / Eisai, Merck (MSD)
Trial completion date: KEYNOTE-146: A Trial of Lenvatinib (E7080) Plus Pembrolizumab in Participants With Selected Solid Tumors (clinicaltrials.gov) - Mar 7, 2022
P1b/2, N=357, Active, not recruiting, Sponsor: Eisai Inc.
Not yet recruiting --> Recruiting Trial completion date: Sep 2023 --> Jun 2022
- Alecensa (alectinib) / Roche
ALK Inhibitor Related Tubular Dysfunction and Electrolyte Abnormalities with Preserved Kidney Function () - Mar 6, 2022 - Abstract #NKFSCM2022NKF_SCM_818;
Although electrolyte derangements are known to occur in patients taking this medication, hypomagnesemia has not been commonly reported. In such a case, the offending agent should be held, and patients should be monitored in a high acuity setting until reversal of damage can occur.
- |||| Keytruda (pembrolizumab) / Merck (MSD), cisplatin / Generic mfg., lenvatinib / Generic mfg.
Clinical: Pembro+Lenvatinib did not improve outcomes as 1st-line therapy for Advanced #urothelialcarcinoma-platinum-ineligible or cisplatin-ineligible PD-L1-high-LEAP-011 trial #GU22-@y_loriot-Poor patient population (PS2~80%) compromised outcomes? https://t.co/slauTuVnPh @practiceupdate (Twitter) - Mar 6, 2022
- || Tyvyt (sintilimab) / Eli Lilly, Focus V (anlotinib) / Advenchen, Sino Biopharm
Clinical, Journal: Complete pathological response with diabetic ketoacidosis to the combination of sintilimab and anlotinib in an unresectable hepatocellular carcinoma patient: a case report. (Pubmed Central) - Mar 5, 2022
Active follow-ups revealed no signs of local recurrence or distant failure. In conclusion, this case report demonstrated that the combination of anlotinib and sintilimab, one of the strategies combining ICIs with AAAs, showed promising efficacy in the treatment of uHCC patients.
- ||| lenvatinib / Generic mfg.
Biomarker, Clinical, Journal, Adverse events: Adverse events as potential predictive factors of activity in advanced hepatocellular carcinoma patients treated with lenvatinib. (Pubmed Central) - Mar 4, 2022
Our main findings are that the occurrence of arterial hypertension G ≥ 2 is a predictor of longer survival, whereas decreased appetite G ≥ 2 predicts for a poor prognosis. A careful management of AEs under lenvatinib treatment for HCC is required, in order to improve patients' quality of life, minimize the need for treatment discontinuation and achieve optimal outcome.